Full formMedical & Health
ERKstands forExtracellular signal-Regulated Kinase
Full Form of ERK
What is ERK?
ERK, short for Extracellular signal-Regulated Kinase, is a type of protein kinase that plays a central role in the MAPK/ERK signaling pathway, which transmits signals from cell surface receptors to the nucleus. This pathway regulates essential cellular processes such as proliferation, differentiation, and survival. In the Indian context, ERK is widely studied in biomedical research laboratories, particularly in cancer biology, where its aberrant activation is linked to tumor growth and metastasis. Research institutions like the Indian Institute of Science and various medical colleges investigate ERK inhibitors for targeted cancer therapies. The term is commonly used in molecular biology and pharmacology classrooms, as well as in NEET PG, CSIR NET Life Sciences, and GATE Biotechnology examinations. Understanding ERK signaling is crucial for students pursuing careers in medicine and life sciences, as it forms the basis for many drug development strategies against cancers and inflammatory diseases. Clinical trials in India often monitor ERK phosphorylation levels as a biomarker for treatment response.
ERK का फुल फॉर्म
बाह्यकोशिकीय संकेत-नियंत्रित काइनेज
Example
Recent studies at the Tata Memorial Centre have identified elevated ERK activity in breast cancer tissues, prompting further investigation into targeted ERK inhibitors.
ERK — frequently asked questions
What is the full form of ERK?
The full form of ERK is Extracellular signal-Regulated Kinase. It is a protein kinase involved in the MAPK signaling pathway that controls cell growth and differentiation.
What is the function of ERK in the body?
ERK transmits signals from growth factors and hormones to the cell nucleus, regulating processes like cell division, survival, and differentiation. Abnormal ERK activity is linked to many cancers.
How is ERK related to cancer treatment in India?
ERK is a target for cancer drugs because its overactivation promotes tumor growth. Indian research institutes are developing ERK inhibitors for targeted therapy, especially in breast and lung cancers.